March Biosciences is dedicated to revolutionizing patient care by discovering and exploiting high-impact targets for cancer immunotherapy. Our lead asset, MB-105, is designed to treat relapse/refractory T-cell malignancies, currently with no effective and curative alternative treatments
Chimeric antigen receptor (CAR) T-cells are a powerful new therapeutic option where T-cells are engineered to specifically target key antigens on tumor cells. This boosts the natural function of T-cells against cancer cells.
1. Collection of T-cells:
leukapheresis is used to isolate T-cells from a patient’s blood.
2. Genetic modification of T-cells:
The patients’ T-cells are genetically engineered in a laboratory to express the CAR, specifically designed to selectively recognize antigens on the cancer cells’ surface.
3. Expansion and activation of CAR T-cells:
The modified T-cells are expanded to increase their numbers and activated to boost their anti-cancer activity.
4. Infusion of CAR T-cells:
Following expansion and activation, the CAR T-cells are infused back into the patient’s bloodstream intravenously.
The engineered CAR-T cells will then circulate, target, and eliminate cancer cells expressing the target antigen.
There is an ongoing Phase 1 clinical trial (NCT03081910) for the autologous CD5 CAR-T, developed at Baylor College of Medicine, for T-cell lymphoma and T-cell acute lymphoblastic leukemia (TCL and T-ALL). Enrollment for this trial is ongoing and available to patients via a referring physician.
News & Publications
Read more about how March Biosciences’ research has impacted the medical community.